minor tweak to intro

Latex/Paper/sections/01_introduction.tex

@@ -47,19 +47,16 @@ Thus being able to isolate the effect of operational challenges from
 strategic decisions allows us to predict the intended or unintended effects
 of a given policy on clinical trials.
 
-In this work, I propose a model of clinical trial progression that allows 
-me to separate the effects of competing drugs (a strategic concern)
-and struggles recruiting (an operational concern).
-I also use a novel dataset extracted from 
+In this work, I focus on separating the effects of enrollment and 
+competing drugs on clinical trial completion, specifically Phase III trials.
+To do this, I create a 
+ dataset extracted from 
 \url{ClinicalTrials.gov} 
 that tracks individual clinical trials as they progress towards completion
-to estimate the effects of competing drugs and difficulty recruiting.
-Similar to 
-\cite{hwang_failure_2016} 
-I focus on clinical trials in Phase III trials for drug compounds. 
-Not all of these trials will be to test novel compounds, as many 
-are trials to use previously approved compounds for new indications
-or in combination with other treatments.
-
+as well as a novel causal model of individual clinical trial progression.
+Unlike previous research which is focused on the drug development pipeline, I 
+restrict my investigation to modelling individual clinical trials.
+The goal of this restriction is to provide a way to predict the impact
+of changes that affect enrollment independent of other confounding effects. 
 
 \end{document}